Bone Biologics (NASDAQ:BBLG) Issues Quarterly Earnings Results, Beats Estimates By $0.86 EPS

Bone Biologics (NASDAQ:BBLG) issued its quarterly earnings data on Friday. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.86, FiscalAI reports.

Bone Biologics Stock Down 5.9%

Shares of BBLG stock traded down $0.10 on Friday, hitting $1.60. 25,015 shares of the stock were exchanged, compared to its average volume of 29,963. The firm’s 50 day moving average is $2.23 and its two-hundred day moving average is $3.17. Bone Biologics has a one year low of $1.55 and a one year high of $10.08.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Wall Street Zen upgraded Bone Biologics from a “sell” rating to a “hold” rating in a research note on Sunday, September 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bone Biologics in a research report on Tuesday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.